We strive to improve the lives of patients with cancer by creating and developing innovative antibody-based products. This commitment is deeply rooted in science.

With a deep knowledge of the power of the human immune system and a proven track record for inventing and engineering novel therapeutic antibodies, we aim to tackle and overcome the challenges in oncology drug development.

In our product discovery, we connect our innovative antibody platform technologies with our robust target and disease biology knowledge to create novel and differentiating products.

Our differentiated pipeline stands as proof of our ability to identify and address the areas of unmet treatment need and includes Tisotumab Vedotin, Genmab’s first therapy approved in the U.S. and multiple Genmab-created* antibodies approved by the U.S. Food and Drug Administration with breakthrough designations— including Daratumumab, Ofatumumab and Teprotumumab.